ProPhase Labs Inc (PRPH) CEO Ted William Karkus Sells 424,789 Shares
ProPhase Labs Inc (NASDAQ:PRPH) CEO Ted William Karkus sold 424,789 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $2.30, for a total value of $977,014.70. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Ted William Karkus also recently made the following trade(s):
- On Friday, September 29th, Ted William Karkus sold 364,950 shares of ProPhase Labs stock. The stock was sold at an average price of $2.30, for a total value of $839,385.00.
Shares of ProPhase Labs Inc (NASDAQ PRPH) traded down $0.01 during trading hours on Tuesday, hitting $2.19. The stock had a trading volume of 1,700 shares, compared to its average volume of 21,230. The stock has a market cap of $27.22, a price-to-earnings ratio of 0.96 and a beta of 0.18. ProPhase Labs Inc has a fifty-two week low of $1.78 and a fifty-two week high of $2.45.
ProPhase Labs declared that its Board of Directors has initiated a stock buyback program on Friday, November 10th that authorizes the company to buyback 1,700,000 shares. This buyback authorization authorizes the company to purchase shares of its stock through a tender offer. Stock buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.
Separately, ValuEngine lowered ProPhase Labs from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th.
About ProPhase Labs
ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.